Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-004979-14
    Sponsor's Protocol Code Number:AR-320-003
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2022-04-28
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2021-004979-14
    A.3Full title of the trial
    A Phase 3, Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Efficacy and Safety of Suvratoxumab in Mechanically Ventilated Adults and Adolescents for the Prevention of Nosocomial Pneumonia
    Estudio en fase III, aleatorizado, doble ciego, controlado con placebo y de dosis única para evaluar la eficacia y la seguridad de suvratoxumab en adultos y adolescentes con ventilación mecánica para la prevención de la neumonía nosocomial
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to see if suvratoxumab is safe and works to stop pneumonia developing in people who are on mechanical ventilators who have a bacteria in their lungs, commonly called Staphylococcus, that has not yet caused an infection.
    Un estudio para ver si suvratoxumab es seguro y funciona para detener el desarrollo de neumonía en personas que reciben respiradores mecánicos que tienen una bacteria en los pulmones, comúnmente llamada Staphylococcus, que aún no ha causado una infección.
    A.3.2Name or abbreviated title of the trial where available
    SAATELLITE-2
    SAATELLITE-2
    A.4.1Sponsor's protocol code numberAR-320-003
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT05331885
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAridis Pharmaceuticals, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAridis Pharmaceuticals, Inc.
    B.4.2CountryUnited States
    B.4.1Name of organisation providing supportCOMBACTE-NET
    B.4.2CountryNetherlands
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAridis Pharmaceuticals, Inc.
    B.5.2Functional name of contact pointClinical Operations
    B.5.3 Address:
    B.5.3.1Street Address983 University Ave, Building B
    B.5.3.2Town/ cityLos Gatos
    B.5.3.3Post codeCA 95032-7637
    B.5.3.4CountryUnited States
    B.5.6E-mailClinicalTrial@aridispharma.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code AR-320
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSUVRATOXUMAB
    D.3.9.2Current sponsor codeAR-320
    D.3.9.3Other descriptive nameMEDI4893
    D.3.9.4EV Substance CodeSUB189814
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Prevention of nosocomial pneumonia
    Prevención de la neumonía nosocomial
    E.1.1.1Medical condition in easily understood language
    Prevention of an infection of the lungs that develops within 48 hours or more of hospital admission and which was not developing at the time of admission.
    Prevención de una infección pulmonar que se desarrolla en las 48 horas siguientes al ingreso en el hospital y que no se estaba desarrollando en el momento del ingreso.
    E.1.1.2Therapeutic area Diseases [C] - Bacterial Infections and Mycoses [C01]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level LLT
    E.1.2Classification code 10052596
    E.1.2Term Nosocomial pneumonia
    E.1.2System Organ Class 100000004862
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the effect of suvratoxumab on reducing the incidence of nosocomial all-cause pneumonia.
    Evaluar el efecto de suvratoxumab en la reducción de la incidencia de neumonía por cualquier causa nosocomial.
    E.2.2Secondary objectives of the trial
    1. To evaluate the safety of a single IV dose of suvratoxumab.
    2. To evaluate the effect of suvratoxumab on reducing the incidence of nosocomial all-cause pneumonia or death.
    3. To evaluate the effect of suvratoxumab on reducing the incidence of nosocomial S. aureus pneumonia.
    4. To evaluate the effect of suvratoxumab on reducing the incidence of long-term nosocomial pneumonia caused by S. aureus.
    5. To measure the effect of suvratoxumab on the magnitude of healthcare utilization.
    6. To evaluate the serum pharmacokinetics (PK) of suvratoxumab.
    7. To evaluate the serum Anti-Drug Antibody (ADA) responses to suvratoxumab.
    1. Evaluar la seguridad de una dosis i.v. única de suvratoxumab.
    2. Evaluar el efecto de suvratoxumab en la reducción de la incidencia de neumonía por cualquier causa nosocomial o la muerte.
    3. Evaluar el efecto de suvratoxumab en la reducción de la incidencia de neumonía nosocomial por S. aureus.
    4. Evaluar el efecto de suvratoxumab en la reducción de la incidencia de neumonía nosocomial a largo plazo causada por S. aureus.
    5. Medir el efecto de suvratoxumab en la magnitud de la utilización de recursos sanitarios.
    6. Evaluar la FC sérica de suvratoxumab.
    7. Evaluar las respuestas de AAF contra suvratoxumab en suero.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Adult (18 [unless otherwise specified by local Country laws] to 65 years of age) or Adolescent (12 to < 18 years of age [unless otherwise specified by local Country laws]) at the time of screening.
    2. Written informed consent and written informed assent and any locally required authorization (e.g., Health Insurance Portability and Accountability Act [HIPPA] in the US, EU Data Privacy Directive in the EU) obtained from the subject/legally acceptable representative (LAR) prior to performing any protocol-related procedures, including screening evaluations.
    3. Females of childbearing potential (inclusive of adolescents) who are sexually active with a non-sterilized male partner must have evidence of not being pregnant upon enrolment and have a negative pregnancy test prior to administration of investigational product.
    - Females of childbearing potential are defined as those who are not surgically sterile (i.e., bilateral oophorectomy, or complete hysterectomy), premenarchal or postmenopausal (defined as 12 months with no menses without an alternative medical cause).
    4. Tracheal or bronchial sample positive by polymerase chain reaction (PCR) for S. aureus within 36 hours prior to randomization. Note: the 36-hour window will be determined by the time of sample collection.
    5. Currently intubated and on mechanical ventilation in the ICU.
    6. Expected to remain intubated and mechanically ventilated for ≥ 3 days based on investigator estimate.
    7. No diagnosis of new-onset pneumonia within 72 hours prior to randomization (subjects with evidence of resolved pneumonia will be eligible).
    1. Adulto (18 [a menos que se especifique lo contrario en las leyes locales del país] a 65 años de edad) adolescente (12 a <18 años de edad [a menos que se especifique lo contrario en las leyes locales del país])
    en el momento de la selección.
    2. Consentimiento informado por escrito y asentimiento informado por escrito, así como todas las autorizaciones locales necesarias (p. ej., la Ley de Portabilidad y Contabilidad de los Seguros de Salud
    [HIPPA] de los Estados Unidos [EE. UU.], la Directiva sobre la privacidad de la Unión Europea [UE]), que se obtendrán del sujeto o su representante legal (RL) antes de llevar a cabo cualquier procedimiento relacionado con el protocolo, incluidas las evaluaciones de selección.
    3. Las mujeres con capacidad de concebir (incluidas las adolescentes) que sean sexualmente activas con una pareja de sexo masculino no esterilizada deben presentar pruebas de no estar embarazadas en el momento de la inscripción y tener una prueba de embarazo negativa antes de la administración del producto en investigación.
    - Las mujeres con capacidad de concebir se definen como aquellas mujeres no esterilizadas quirúrgicamente (es decir, ovariectomía bilateral o histerectomía completa), premenárquicas o posmenopáusicas (definida como 12 meses sin menstruación sin una causa médica alternativa).
    4. Muestra traqueal o bronquial positiva mediante reacción en cadena de la polimerasa (PCR) para S. aureus en las 36 horas anteriores a la aleatorización. Nota: el margen de 36 horas se determinará en función del momento de la obtención de la muestra.
    5. Está actualmente intubado y con ventilación mecánica en la UCI.
    6. Se espera que permanezca intubado y con ventilación mecánica durante ≥ 3 días según la estimación del investigador.
    7. Ausencia de diagnóstico de neumonía de nueva aparición en las 72 horas anteriores a la aleatorización (los sujetos con indicios de neumonía resuelta serán aptos).
    E.4Principal exclusion criteria
    1. The study subject is moribund or unlikely to survive for a week post randomization despite delivery of adequate antibiotics and supportive care, based on clinical judgement by the PI.
    2. Acute confirmed or suspected active S. aureus disease at study enrolment and investigational product dosing (colonization is acceptable as per inclusion criterion #4).
    3. Active pulmonary disease that would impair the ability to diagnose pneumonia, such as active tuberculosis or fungal disease, obstructing lung cancer, large empyema, cystic fibrosis, or acute respiratory distress syndrome with lung "white out".
    4. Receipt of anti- S. aureus systemic antibiotics for > 48 hours within 72 hours prior to randomization that are considered active against the S. aureus strain with which the subject is colonized, or anticipated ongoing receipt of anti- S. aureus systemic antibiotics.
    5. APACHE-II score ≥ 25 (if Glasgow Coma Scale [GCS] score is > 5) or ≥ 30 (if GCS score is ≤ 5), or SOFA score ≥ 9 at time of randomization.
    - Note: Vasopressors only used to improve cerebral perfusion pressure (e.g., subarachnoid hemorrhage) will not be entered in the calculation of the cardiovascular component of the SOFA score.
    6. Receipt of any investigational drug therapy within 30 days prior to randomization.
    7. Previous receipt of a mAb within 60 days prior to randomization.
    8. Subjects with a CD4 count of < 200 due to advanced human immunodeficiency virus (HIV) infection. Subjects with a history of HIV infection who have been on highly active antiretroviral therapy and asymptomatic from HIV infection for at least 6 months may be enrolled.
    9. History of allergic disease or reactions likely to be exacerbated by any component of the investigational product.
    10. Not able to complete long-term follow-up for at least 90 days post dose based on investigator judgment.
    11. Pregnant female or nursing mother.
    1. El sujeto del estudio está moribundo o es poco probable que sobreviviera durante una semana después de la aleatorización a pesar de recibir antibióticos adecuados y tratamiento sintomático según el criterio clínico del investigador principal (IP).
    2. Enfermedad aguda activa confirmada o sospechada por S. aureus en el momento de la inscripción en el estudio y de la administración del producto en investigación (la colonización es aceptable según el criterio
    de inclusión n.º 4).
    3. Enfermedad pulmonar activa que pudiera alterar la capacidad de diagnosticar neumonía, como tuberculosis activa o enfermedad fúngica, cáncer de pulmón obstructivo, empiema grande, fibrosis quística o síndrome
    de dificultad respiratoria aguda con opacidad pulmonar.
    4. Administración de antibióticos sistémicos contra S. aureus durante >48 horas en las 72 horas anteriores a la aleatorización que se consideren activos frente a la cepa de S. aureus con la que el sujeto está colonizado o
    se prevé la administración continuada de antibióticos sistémicos contra S. aureus.
    5. Puntuación de la Evaluación fisiológica aguda y de salud crónica (Acute Physiology and Chronic Health Evaluation, APACHE)-II ≥25 (si la puntuación de la escala de coma de Glasgow [Glasgow Coma Scale, GCS] es >5) o ≥30 (si la puntuación de la GCS es ≤5), o puntuación de la Evaluación de fallo orgánico secuencial (Sequential Organ Failure Assessment, SOFA) ≥9 en el momento de la aleatorización.
    - Nota: los vasopresores que solo se utilicen para mejorar la presión de la perfusión cerebral (p. ej., hemorragia subaracnoidea) no se introducirán en el cálculo del componente cardiovascular de la puntuación SOFA.
    6. Administración de cualquier tratamiento farmacológico en investigación en los 30 días anteriores a la aleatorización.
    7. Administración previa de un AcM en los 60 días anteriores a la aleatorización.
    8. Sujetos con un recuento de CD4 <200 debido a infección avanzada por el virus de la inmunodeficiencia humana (VIH). Se puede incluir a los sujetos con antecedentes de infección por VIH que hayan estado recibiendo tratamiento antirretroviral altamente activo y haya permanecido asintomáticos de infección por VIH durante al menos 6 meses.
    9. Antecedentes de enfermedad alérgica o reacciones susceptibles de exacerbarse por cualquier componente del producto en investigación.
    10. No ser capaz de completar el seguimiento a largo plazo durante al menos 90 días después de la dosis en base al criterio del investigador.
    11. Mujeres embarazadas o en periodo de lactancia.
    E.5 End points
    E.5.1Primary end point(s)
    Incidence of nosocomial all-cause pneumonia through 30 days post dose.
    Incidencia de neumonía por cualquier causa nosocomial hasta 30 días después de la dosis.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Any time through 30 days post dose.
    En cualquier momento hasta 30 días después de la dosis.
    E.5.2Secondary end point(s)
    1. TEAEs and clinical laboratory assessments through 30 days post dose, and TESAEs and TEAEs of special interest (TEAESI) through 90 days, and for a subset of subjects through 180 days post dose.
    2. Incidence of nosocomial all-cause pneumonia or death through 30 days post dose.
    3. Incidence of nosocomial S. aureus pneumonia through 30 days post dose.
    4. Incidence of nosocomial pneumonia caused by S. aureus through 90 days post dose.
    5. Magnitude of healthcare utilization (e.g., duration of mechanical ventilation, duration of ICU stay, duration of hospital stay, number of and days of systemic antibiotic use) through 90 days post dose in all subjects and in a subset of subjects through 180 days post dose.
    6. Suvratoxumab serum concentration and PK parameters through 30 days post dose, and in a subset of subjects through 90 days post dose.
    7. Suvratoxumab ADA response in serum through 30 days post dose, and in a subset of subjects through 90 days post dose.
    1. Acontecimientos adversos surgidos durante el tratamiento (AAST) y evaluaciones analíticas clínicas hasta 30 días después de la dosis, y acontecimientos adversos graves surgidos durante el tratamiento (AAGST) y AAST de especial interés (AASTEI) hasta 90 días, y para un subgrupo de sujetos hasta 180 días después de la dosis.
    2. Incidencia de neumonía por cualquier causa nosocomial o muerte hasta 30 días después de la dosis.
    3. Incidencia de neumonía nosocomial por S. aureus hasta 30 días después de la dosis.
    4. Incidencia de neumonía nosocomial causada por S. aureus hasta 90 días después de la dosis.
    5. Magnitud de la utilización de recursos sanitarios (p. ej., duración de la ventilación mecánica, duración de la estancia en la UCI, duración de la estancia en el hospital, número y días de uso de antibióticos sistémicos) hasta 90 días después de la dosis en todos los sujetos y en un subgrupo de sujetos hasta 180 días después de la dosis.
    6. Concentración sérica y parámetros FC de suvratoxumab hasta 30 días después de la dosis, y en un subgrupo de pacientes hasta 90 días después de la dosis.
    7. Respuesta de AAF contra suvratoxumab en suero hasta 30 días después de la dosis, y en un subgrupo de pacientes hasta 90 días después de la dosis.
    E.5.2.1Timepoint(s) of evaluation of this end point
    1. Any time through 30 days post dose; any time through 90 days post dose; in a subset of subjects any time through 180 days post dose.
    2. Any time through 30 days post dose.
    3. Any time through 30 days post dose.
    4. Any time through 90 days post dose.
    5. Any time through 90 days post dose; in a subset of subjects any time through 180 days post dose.
    6. Any time through 30 days post dose; in a subset of subjects any time through 90 days post dose.
    7. Any time through 30 days post dose; in a subset of subjects any time through 90 days post dose.
    1. En cualquier momento hasta 30 días después de la dosis; en cualquier momento hasta 90 días después de la dosis; en un subgrupo de sujetos en cualquier momento hasta 180 días después de la dosis
    2. En cualquier momento hasta 30 días después de la dosis
    3. En cualquier momento hasta 30 días después de la dosis
    4. En cualquier momento hasta 90 días después de la dosis
    5. En cualquier momento hasta 90 días después de la dosis; en un subgrupo de sujetos en cualquier momento hasta 180 días después de la dosis
    6. En cualquier momento hasta 30 días después de la dosis; en un subgrupo de sujetos en cualquier momento hasta 90 días después de la dosis
    7. En cualquier momento hasta 30 días después de la dosis; en un subgrupo de sujetos en cualquier momento hasta 90 días después de la dosis
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis Yes
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned8
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA65
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Israel
    United States
    Belgium
    France
    Greece
    Portugal
    Netherlands
    Spain
    Switzerland
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the trial is defined as the date of the last protocol - specified visit/ assessment (including telephone contact) for the last subject in the study.
    El final del ensayo se define como la fecha de la última visita/evaluación especificada en el protocolo (incluido el contacto telefónico) para el último sujeto del estudio.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months18
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months6
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 14
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 14
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 550
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception Yes
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Intubated and on mechanical ventilation in the Intensive Care Unit (ICU).
    Intubado y con ventilación mecánica en la Unidad de Cuidados Intensivos (UCI).
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state27
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 105
    F.4.2.2In the whole clinical trial 564
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None.
    Ninguno.
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    G.4.1Name of Organisation COMBACTE-NET
    G.4.3.4Network Country Netherlands
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-08-18
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-08-11
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 21:23:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA